查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925539

第三方医疗检测服务市场（按检测类型、技术、检体类型、最终用户和应用划分）—2026-2032年全球预测

Third-party Medical Testing Services Market by Test Type, Technology, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，第三方医疗检测服务市场规模将达到 39.4 亿美元，到 2026 年将成长至 43 亿美元，到 2032 年将达到 78.4 亿美元，复合年增长率为 10.31%。

关键市场统计数据
基准年 2025 39.4亿美元
预计年份：2026年 43亿美元
预测年份 2032 78.4亿美元
复合年增长率 (%) 10.31%

针对不断变化的第三方医疗检测环境，制定策略方法，明确临床检查室的驱动因素、营运要务和产能优先事项。

本执行摘要概述了第三方医疗检测服务的现状，并阐述了构成该行业的核心结构因素和相关人员的期望。临床检查室、诊断中心和医院网路在一个不断变化的生态系统中运营，其特点是检测项目日益复杂、对检测结果的速度和准确性要求不断提高，以及报销机制和监管压力不断演变。在此背景下，具备营运灵活性和深厚技术实力的服务提供者更有能力在控製成本的同时满足临床医生和患者的需求。

技术创新、不断变化的法规和供应链韧性将如何共同重新定义诊断检测服务的竞争优势和价值创造

外包诊断检测市场正受到变革性力量的重塑，而这些力量远不止于简单的技术替代。分子诊断技术的快速发展，特别是定序和聚合酵素链锁反应）技术的临床应用不断扩展，使得疾病检测更加精准，治疗方案也更加个人化。同时，自动化和数位化检查室解决方案正在简化检体处理和资料流，减少人工操作造成的误差，并加快检测速度。这些技术进步正推动检测产业向高价值的专业检测转型，同时也拓展了第三方可进行的检测范围。

为因应2025年美国关税调整，营运和采购的调整日益重视供应链韧性和成本透明度。

美国2025年实施的关税和贸易政策趋势为诊断检测供应链带来了新的成本和物流方面的挑战。进口关税及相关合规要求大幅提高了关键检测设备、试剂和耗材的到岸成本。这迫使采购和营运团队重新评估其筹资策略和库存管理实务。为此，检查室负责人正在审查供应商合同，尽可能探索本地生产，并调整库存缓衝，以降低供应中断和交付不确定性的风险。

将检测类型、技术、最终用户、应用和检体类型与检查室运营和能力优先事项联繫起来的综合细分观点

对细分市场的深入理解揭示了技术能力与临床需求和营运模式相符的领域。按检测类型划分，临床化学（细分为自动化化学分析仪和照护现场化学检测）以及血液学、组织病理学、免疫学、微生物学和分子诊断（分子诊断又细分为次世代定序和PCR）均得到服务。这种多样性决定了对资金和专业知识的不同需求：自动化化学平台优先考虑通量和可重复性，而分子检测则需要严格的污染控制和生物资讯能力。

美洲、欧洲、中东和非洲以及亚太地区的区域战略差异和营运重点会影响服务模式和伙伴关係关係策略。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的需求模式和营运策略。在美洲，医疗系统优先考虑整合、规模化和快速采用高通量平台，而公立和私立支付方则继续透过报销政策和合约实践影响医疗服务利用趋势。这种环境有利于那些能够大规模提供稳定高品质服务并能与电子健康记录和国家卫生数据基础设施实现互通性的医疗服务提供者。

竞争格局洞察：揭示设备製造商、专业诊断公司和侦测网路如何利用合作关係和创新来实现差异化竞争

竞争动态由成熟的仪器製造商、专业的分子诊断公司、大型检测服务供应商以及新兴的平台创新者共同塑造。供应商不断透过整合硬体、试剂和软体支援的解决方案来推动市场应用，使检查室能够提高检测通量、增强结果的可重复性并简化维护。同时，专业的分子诊断和定序公司正透过将产品与精简的工作流程结合，拓展其在临床市场的业务，从而提供临床检验证据并加快结果出炉速度。

为诊断领导者提供切实可行的优先行动方案，以增强平台柔软性、供应商韧性、证据产生、员工能力和数位化整合。

产业领导者应采取务实且优先的行动方案，使产能投资与不断变化的临床需求和营运韧性保持一致。首先，选择性地投资于模组化、可互通的平台，这些平台既支援高通量自动化化学检测，也支援先进的分子工作流程，从而能够灵活适应不断变化的检测组合。其次，加强供应商多元化和优化合约条款，以降低关税带来的供应风险，同时促进短期供应的连续性和长期成本的透明度。

调查方法透明度：说明如何将一手访谈、实地观察、二手资料和专家检验结合，从而得出可操作的检查室。

本研究结合了一手和二手研究方法，以确保研究结果得到稳健且多层次的检验。一手研究包括对实验室主任、采购人员、临床相关人员和技术供应商进行结构化访谈，以及实地考察和工作流程观察，以实际操作资料佐证定性研究结果。二手研究涵盖行业文献、监管指导文件、技术白皮书和製造商规格说明，以阐明技术能力和合规要求。

将技术准备、供应链策略、监管合规性和伙伴关係模式与永续竞争优势连结起来的综合结论

分析结果表明，第三方医疗检测服务正处于一个转折点，技术能力、合规性和供应链韧性将共同决定其竞争优势。专注于投资互通平台并建立多元化供应商关係的机构，将更有能力提供一致的临床质量，同时克服贸易相关的成本和物流压力。同时，未能将证据生成与临床效用相结合的机构，则可能面临推广速度放缓和支付方支持不足的风险。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 第三方医疗检测服务市场（依检测类型划分）

  • 临床化学
    • 自动化学分析仪
    • 照护现场化学检测
  • 血液学
  • 组织病理学
  • 免疫学
  • 微生物学
  • 分子诊断
    • 次世代定序
    • PCR

9. 按技术分類的第三方医疗检测服务市场

  • 免疫检测
  • 质谱分析
  • 显微镜
  • PCR
    • 数位PCR
    • 定量PCR
  • 定序

第十章：依检体类型分類的第三方医疗检测服务市场

  • 血
    • 电浆
    • 血清
    • 全血
  • 唾液
  • 组织
  • 尿

第十一章 以最终用户分類的第三方医疗检测服务市场

  • 学术研究机构
  • 诊断中心
  • 医院
    • 私立医院
    • 公立医院
  • 製药和生物技术公司

第十二章 第三方医疗检测服务市场（按应用领域划分）

  • 心臟病学
  • 基因检测
  • 感染疾病
  • 神经病学
  • 肿瘤学
    • 液态生物检体
    • 组织切片检查

第十三章 第三方医疗检测服务市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 第三方医疗检测服务市场（以群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国第三方医疗检测服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国第三方医疗检测服务市场

第十七章：中国第三方医疗检测服务市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ARUP Laboratories LLC
  • Bio-Reference Laboratories Inc
  • Cerba Healthcare SA
  • Cerberus Diagnostics Inc
  • Charles River Laboratories International Inc
  • Element Materials Technology Ltd
  • Eurofins Scientific SE
  • Fulgent Genetics Inc
  • ICON plc
  • Intertek Group plc
  • IQVIA Holdings Inc
  • Labcorp Holdings Inc
  • Mayo Foundation for Medical Education and Research
  • Medpace Holdings Inc
  • NeoGenomics Laboratories Inc
  • OPKO Health Inc
  • PPD Inc
  • Quest Diagnostics Incorporated
  • SGS SA
  • Sonic Healthcare Limited
  • SYNLAB AG
  • TUV SUD AG
  • Unilabs Holding SA
  • WuXi AppTec Co Ltd
Product Code: MRR-7A380DA7C6A2

The Third-party Medical Testing Services Market was valued at USD 3.94 billion in 2025 and is projected to grow to USD 4.30 billion in 2026, with a CAGR of 10.31%, reaching USD 7.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.94 billion
Estimated Year [2026] USD 4.30 billion
Forecast Year [2032] USD 7.84 billion
CAGR (%) 10.31%

A strategic orientation to the evolving third-party medical testing landscape that clarifies drivers, operational imperatives, and capability priorities for clinical laboratories

This executive summary frames the contemporary landscape for third-party medical testing services, outlining the core structural forces and stakeholder expectations that define the sector. Clinical laboratories, diagnostic centers, and hospital networks are operating within a shifting ecosystem characterized by rising complexity in test portfolios, a heightened emphasis on turn-around time and accuracy, and evolving reimbursement and regulatory pressures. In this context, providers that combine operational agility with deep technical capability are better positioned to meet clinician and patient needs while controlling costs.

The industry is also undergoing a technology-led reconfiguration where advanced molecular platforms, automation in clinical chemistry, and integrated information systems play an increasingly central role. These technological shifts are influencing how samples are processed, how results are reported, and how laboratories collaborate with pharmaceutical companies and academic research institutions. At the same time, changing patterns in care delivery, including outpatient diagnostics and decentralized testing models, are redefining the interplay between centralized reference labs and point-of-care services. Consequently, executives must reconcile legacy laboratory processes with the imperative to adopt flexible, interoperable platforms that support new test modalities and data-driven decision-making.

Taken together, these dynamics demand strategic clarity around capability investments, partnerships, and talent models. The remainder of this summary unpacks the transformative shifts, tariff implications, segmentation insights, regional differentiators, competitive movements, and practical recommendations that will guide effective decision-making in the near term.

How technological advances, regulatory evolution, and supply chain resilience are jointly redefining competitive advantage and value creation in diagnostic testing services

The marketplace for outsourced diagnostic testing is being reshaped by a constellation of transformative forces that extend beyond simple technological substitution. Rapid advances in molecular diagnostics, particularly the broader clinical application of sequencing and polymerase chain reaction techniques, are enabling more precise disease detection and personalized therapy selection. Concurrently, automation and digital laboratory solutions are streamlining sample handling and data flows, which reduces manual variability and accelerates result delivery. These technical developments are reinforcing a shift toward higher-value, specialized testing while expanding the scope of tests that can be feasibly offered by third-party providers.

In parallel, regulatory rigor and quality expectations have intensified, prompting laboratories to invest in standardized procedures, robust quality controls, and accreditation pathways. Payer behavior and clinical guideline evolution are exerting pressure on test utilization patterns, encouraging clearer clinical validation and outcome linkage. Moreover, supply chain resilience has become an operational priority, with procurement teams diversifying sources and building redundancy for critical reagents and instrumentation. As a result, strategic partnerships, vendor consolidation, and targeted alliances between diagnostic companies and clinical laboratories have become commonplace.

Finally, patient-centric care models and health system consolidation are altering referral flows and demand geography. Decentralized testing and point-of-care modalities are growing alongside centralized reference services, creating hybrid service models. The cumulative effect is a marketplace where technical excellence, quality governance, and strategic connectivity determine competitive positioning and long-term viability.

Operational and procurement adaptations driven by 2025 United States tariff adjustments that have increased emphasis on supply chain resilience and cost transparency

Tariff and trade policy developments in the United States for 2025 introduced new cost and logistics considerations that reverberate across the diagnostic testing supply chain. Import duties and related compliance requirements have increased the effective landed cost of critical laboratory equipment, reagents, and consumables, which in turn has forced procurement and operations teams to reassess sourcing strategies and inventory approaches. In response, laboratory leaders have revisited supplier contracts, sought local manufacturing where feasible, and adjusted inventory buffers to mitigate disruption risk and delivery lead time uncertainty.

Beyond procurement, the tariff landscape has sharpened focus on total cost of ownership, prompting organizations to evaluate equipment interoperability, maintenance contracts, and consumable dependencies more closely. Longer-term service agreements and multi-supplier sourcing arrangements have become pragmatic responses to avoid overreliance on single vendors whose components may be subject to fluctuating trade barriers. Regulatory compliance and customs classification accuracy have also risen in priority to avoid unexpected tariff application or clearance delays that can affect testing continuity.

Operational teams have responded with workflow and scheduling adaptations to smooth throughput during periods of constrained supply. Partnerships with regional suppliers and investment in platform-agnostic assays have reduced exposure to trade-related volatility. Overall, the tariff environment has accelerated strategic behaviors that emphasize resilience, contractual flexibility, and closer alignment between procurement, quality, and clinical operations.

Integrated segmentation perspectives linking test types, technologies, end users, applications, and sample types to operational and capability priorities for laboratories

A nuanced understanding of segmentation reveals where technical capacity aligns with clinical demand and operational models. By test type, services encompass Clinical Chemistry-further delineated into Automated Chemistry Analyzers and Point of Care Chemistry Testing-alongside Hematology, Histopathology, Immunology, Microbiology, and Molecular Diagnostics, with Molecular Diagnostics further characterized by Next Generation Sequencing and PCR. This diversity creates differentiated capital and expertise requirements, with automated chemistry platforms prioritizing throughput and reproducibility, and molecular modalities demanding stringent contamination control and bioinformatics capability.

When considering end users, the landscape includes Academic And Research Institutes, Diagnostic Centers, Hospitals, and Pharmaceutical And Biotech Companies, where Hospitals are further categorized into Private Hospitals and Public Hospitals. Each end user type brings distinct service expectations: academic and research institutions often require specialized assays and data sharing for studies, diagnostic centers value rapid turnarounds and scalable workflows, hospitals prioritize integration with clinical systems and on-site logistics, and industry customers demand analytical rigor and compliance for clinical trials and companion diagnostics.

Technology segmentation spans Immunoassays, Mass Spectrometry, Microscopy, PCR, and Sequencing, with PCR further broken down into Digital PCR and Quantitative PCR. Application areas include Cardiology, Genetic Testing, Infectious Diseases, Neurology, and Oncology, where Oncology itself is delineated into Liquid Biopsy and Tissue Biopsy. Sample types range across Blood, Saliva, Tissue, and Urine, with Blood further divided into Plasma, Serum, and Whole Blood. These intersecting vectors inform decisions about laboratory layout, staffing, quality systems, and informatics, and they guide which value propositions resonate with varied clinical and commercial stakeholders.

Regional strategic contrasts and operational priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence service models and partnership strategies

Regional dynamics shape both demand patterns and operational strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems emphasize consolidation, scale, and rapid adoption of high-throughput platforms, and private and public payers continue to influence utilization through reimbursement policy and contracting practices. This environment favors providers that can deliver consistent quality at scale and that demonstrate interoperability with electronic health records and national health data infrastructure.

Across Europe, Middle East & Africa, regulatory complexity and heterogeneous payer landscapes create differentiated entry and operational models. Laboratories and service providers in this region must navigate diverse accreditation standards, cross-border logistics, and variable clinical guideline adoption while capitalizing on pockets of innovation in molecular diagnostics and centralized testing collaborations. The region often requires tailored service and compliance approaches that reflect local clinical pathways and procurement norms.

In Asia-Pacific, rapid investment in healthcare infrastructure, coupled with a strong focus on precision medicine initiatives in several markets, is driving demand for both centralized reference testing and decentralized modalities. Procurement strategies tend to balance cost sensitivity with a willingness to adopt novel technologies that demonstrate clear clinical utility. Across all regions, cross-border partnerships, regional manufacturing, and adaptive regulatory strategies are important mechanisms by which providers manage complexity and optimize service delivery.

Competitive landscape insights showing how instrument providers, specialty diagnostics firms, and laboratory networks are leveraging partnerships and innovation to differentiate

Competitive dynamics are shaped by a mix of established instrument manufacturers, specialized molecular diagnostics firms, large laboratory service providers, and emerging platform innovators. Instrument vendors continue to drive adoption through integrated solutions that combine hardware, reagents, and software support, enabling laboratories to upgrade throughput and enhance reproducibility while simplifying maintenance. At the same time, specialist molecular and sequencing companies are expanding into clinical markets by aligning their offerings with clinical validation evidence and streamlined workflows that reduce time to result.

Large laboratory service providers maintain competitive advantage through scale, logistics networks, and integration into clinical care pathways, often leveraging their size to secure favorable supplier terms and to invest in automation. Meanwhile, start-ups and technology-focused newcomers push innovation in areas such as digital PCR, liquid biopsy analytics, and lab automation, forcing incumbents to accelerate modernization. Partnerships and horizontal integrations have become common approaches to broaden test menus and to enter new geographic markets without the full capital outlay of greenfield facilities.

Strategic differentiation increasingly rests on the ability to combine technical excellence with commercialization capabilities, including clinician engagement, payer alignment, and evidence generation. Companies that can demonstrate clinical utility, streamline onboarding for health systems, and provide robust customer support are more successful in securing long-term contracts and collaborative research partnerships.

Practical, prioritized actions for diagnostic leaders to enhance platform flexibility, supplier resilience, evidence generation, workforce capability, and digital integration

Industry leaders should adopt a set of pragmatic, prioritized actions that align capability investment with evolving clinical demand and operational resilience. First, invest selectively in modular, interoperable platforms that support both high-throughput automated chemistry and advanced molecular workflows, thereby preserving flexibility as test mixes shift. Second, strengthen supplier diversification and contractual terms to mitigate tariff-induced supply risks while promoting near-term continuity and long-term cost transparency.

Third, align commercial and clinical strategies by building stronger evidence-generation capabilities that link diagnostic results to actionable clinical outcomes, which supports payer negotiations and clinician adoption. Fourth, deploy workforce development programs focused on molecular techniques, bioinformatics, and laboratory automation to bridge skills gaps. Fifth, pursue targeted regional strategies that reflect local regulatory, reimbursement, and clinical practice differences, leveraging partnerships with regional players where appropriate to accelerate market entry.

Finally, accelerate digital integration across laboratory information systems, result reporting, and clinician-facing platforms to improve throughput, reduce errors, and support data-driven service design. Executing these recommendations will require coordinated governance, clear prioritization of capital allocation, and continuous monitoring of regulatory and trade developments to adapt quickly as circumstances evolve.

Methodological transparency describing how primary interviews, site observations, secondary sources, and expert validation were combined to produce actionable laboratory insights

This research synthesized primary and secondary methods to ensure robust, multilevel validation of insights. Primary research included structured interviews with laboratory directors, procurement leads, clinical stakeholders, and technology vendors, combined with site visits and workflow observations to ground qualitative findings in operational reality. Secondary research encompassed industry literature, regulatory guidance documents, technical white papers, and manufacturer specifications to contextualize technology capabilities and compliance requirements.

Data triangulation was achieved by cross-referencing interview inputs with publicly available regulatory filings, corporate disclosures, and technical specifications to identify consistent patterns and to reconcile divergent viewpoints. Quality assurance included peer review of methodology and findings by domain experts in laboratory operations, molecular diagnostics, and healthcare economics. Segmentation mapping aligned test types, technologies, applications, sample types, and end-user characteristics to ensure that analyses reflected the practical intersections that determine service design and capability needs.

Limitations and mitigations are transparently documented, including the dynamic nature of regulatory environments and trade policies, which the methodology addressed by incorporating the most current guidance and by validating operational implications through multiple stakeholder perspectives. This approach produced actionable intelligence that balances rigor with practical relevance for industry decision-makers.

Concluding synthesis that ties technological readiness, supply chain strategies, regulatory navigation, and partnership models to sustainable competitive positioning

This body of analysis concludes that third-party medical testing services are at an inflection point where technological capability, regulatory compliance, and supply chain resilience collectively determine competitive advantage. Providers that invest in interoperable platforms and cultivate diversified supplier relationships will be better equipped to navigate trade-related cost and logistics pressures while delivering consistent clinical quality. At the same time, those that fail to align evidence generation with clinical utility risk slower adoption and constrained payer support.

Moreover, regional nuances demand tailored approaches that respect local regulatory frameworks, reimbursement models, and clinical practice patterns. Strategic partnerships, whether for regional distribution, co-development, or shared laboratory capacity, offer a pragmatic pathway to expansion without undue capital strain. Workforce capability and digital integration are persistent enablers; investments in these areas yield improvements in throughput, error reduction, and clinician satisfaction.

In sum, successful organizations will combine technical excellence with operational discipline, strategic supplier management, and clinician-focused commercialization to capture durable value. The recommendations outlined provide a roadmap for executives to prioritize investments and to structure cross-functional initiatives that translate insights into measurable operational improvements and stronger clinical partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Third-party Medical Testing Services Market, by Test Type

  • 8.1. Clinical Chemistry
    • 8.1.1. Automated Chemistry Analyzers
    • 8.1.2. Point Of Care Chemistry Testing
  • 8.2. Hematology
  • 8.3. Histopathology
  • 8.4. Immunology
  • 8.5. Microbiology
  • 8.6. Molecular Diagnostics
    • 8.6.1. Next Generation Sequencing
    • 8.6.2. PCR

9. Third-party Medical Testing Services Market, by Technology

  • 9.1. Immunoassays
  • 9.2. Mass Spectrometry
  • 9.3. Microscopy
  • 9.4. PCR
    • 9.4.1. Digital PCR
    • 9.4.2. Quantitative PCR
  • 9.5. Sequencing

10. Third-party Medical Testing Services Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Saliva
  • 10.3. Tissue
  • 10.4. Urine

11. Third-party Medical Testing Services Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals
  • 11.4. Pharmaceutical And Biotech Companies

12. Third-party Medical Testing Services Market, by Application

  • 12.1. Cardiology
  • 12.2. Genetic Testing
  • 12.3. Infectious Diseases
  • 12.4. Neurology
  • 12.5. Oncology
    • 12.5.1. Liquid Biopsy
    • 12.5.2. Tissue Biopsy

13. Third-party Medical Testing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Third-party Medical Testing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Third-party Medical Testing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Third-party Medical Testing Services Market

17. China Third-party Medical Testing Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ARUP Laboratories LLC
  • 18.6. Bio-Reference Laboratories Inc
  • 18.7. Cerba Healthcare SA
  • 18.8. Cerberus Diagnostics Inc
  • 18.9. Charles River Laboratories International Inc
  • 18.10. Element Materials Technology Ltd
  • 18.11. Eurofins Scientific SE
  • 18.12. Fulgent Genetics Inc
  • 18.13. ICON plc
  • 18.14. Intertek Group plc
  • 18.15. IQVIA Holdings Inc
  • 18.16. Labcorp Holdings Inc
  • 18.17. Mayo Foundation for Medical Education and Research
  • 18.18. Medpace Holdings Inc
  • 18.19. NeoGenomics Laboratories Inc
  • 18.20. OPKO Health Inc
  • 18.21. PPD Inc
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. SGS SA
  • 18.24. Sonic Healthcare Limited
  • 18.25. SYNLAB AG
  • 18.26. TUV SUD AG
  • 18.27. Unilabs Holding SA
  • 18.28. WuXi AppTec Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 240. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 276. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 278. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET